Chimeric antigen receptor T (<scp>CAR‐T</scp>) cells: Novel cell therapy for hematological malignancies

Abbasi, Samane; Totmaj, Milad Asghari; Abbasi, Masoumeh; Hajazimian, Saba; Goleij, Pouya; Behroozi, Javad; Shademan, Behrouz; Isazadeh, Alireza; Baradaran, Behzad

doi:10.1002/cam4.5551

Cited by 35 publications

(15 citation statements)

References 132 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This process enables the recruitment and phosphorylation of the cascade proteins downstream, such as CD3ζ and CMs. Following activation, the CAR-T cells go through a proliferative and differentiating process that is necessary for the effector functions or the ability of the CAR-T cells to kill cancer [96].…”

Section: Mechanism Of Action Of Car-t Therapymentioning

confidence: 99%

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy

Kalim,

Jing,

et al. 2024

J Cell Immunol

View full text Add to dashboard Cite

Chimeric antigen receptor (CAR)-T cell therapy has shown potential in improving outcomes for individuals with hematological malignancies. However, achieving long-term full remission for blood cancer remains challenging due to severe life-threatening toxicities such as limited anti-tumor efficacy, antigen escape, trafficking restrictions, and limited tumor invasion. Furthermore, the interactions between CAR-T cells and their host tumor microenvironments have a significant impact on CAR-T function. To overcome these considerable hurdles, fresh methodologies and approaches are needed to produce more powerful CAR-T cells with greater anti-tumor activity and less toxicity. Despite advances in CAR-T research, microbial resistance remains a significant obstacle. In this review, we discuss and describe the basics of CAR-T structures, generations, challenges, and potential risks of infections in CAR-T cell therapy.

show abstract

Section: Mechanism Of Action Of Car-t Therapymentioning

confidence: 99%

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy

Kalim,

Jing,

et al. 2024

J Cell Immunol

View full text Add to dashboard Cite

show abstract

“…Although they enhance functioning of the immune system to combat pancreatic cancer via different mechanisms, each therapeutic strategy has its own unique advantages and disadvantages ( Figure 3 ). ACT offers the advantages of individualized treatment and durable antitumor effects, but is associated with the disadvantages of complex preparation methods and high costs ( 145 , 146 ). Oncolytic viruses (OVs) offer the advantage of selectively infecting cancer cells and inducing immune responses; however, the process of selective infection needs to be improved and the replication ability is limited ( 147 ).…”

Section: Other Immune-related Therapiesmentioning

confidence: 99%

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

Zheng,

Liu,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Pancreatic cancer is a highly aggressive malignant tumor, that is becoming increasingly common in recent years. Despite advances in intensive treatment modalities including surgery, radiotherapy, biological therapy, and targeted therapy, the overall survival rate has not significantly improved in patients with pancreatic cancer. This may be attributed to the insidious onset, unknown pathophysiology, and poor prognosis of the disease. It is therefore essential to identify and develop more effective and safer treatments for pancreatic cancer. Tumor immunotherapy is the new and fourth pillar of anti-tumor therapy after surgery, radiotherapy, and chemotherapy. Significant progress has made in the use of immunotherapy for a wide variety of malignant tumors in recent years; a breakthrough has also been made in the treatment of pancreatic cancer. This review describes the advances in immune checkpoint inhibitors, cancer vaccines, adoptive cell therapy, oncolytic virus, and matrix-depletion therapies for the treatment of pancreatic cancer. At the same time, some new potential biomarkers and potential immunotherapy combinations for pancreatic cancer are discussed. The molecular mechanisms of various immunotherapies have also been elucidated, and their clinical applications have been highlighted. The current challenges associated with immunotherapy and proposed strategies that hold promise in overcoming these limitations have also been discussed, with the aim of offering new insights into immunotherapy for pancreatic cancer.

show abstract

“…Advancing towards adoptive cell therapies, CAR-T/TCR-T are being less utilized due to safety-concerns and off-target outcomes [ 201 – 203 ]. However, these agents have been successfully used in treating hematological tumors and in combination with the small molecule inhibitors for solid tumors [ 204 , 205 ]. With the oncolytic viruses, there occurs confrontation of targeted delivery of virus, as the virus needs to get past the systemic immune forces of the body.…”

Section: Clinical Implications Of Cancer Immunotherapymentioning

confidence: 99%

The future of cancer immunotherapy: DNA vaccines leading the way

et al. 2023

View full text Add to dashboard Cite

Immuno-oncology has revolutionized cancer treatment and has opened up new opportunities for developing vaccination methods. DNA-based cancer vaccines have emerged as a promising approach to activating the bodily immune system against cancer. Plasmid DNA immunizations have shown a favorable safety profile and there occurs induction of generalized as well as tailored immune responses in preclinical and early-phase clinical experiments. However, these vaccines have notable limitations in immunogenicity and heterogeneity and these require refinements. DNA vaccine technology has been focusing on improving vaccine efficacy and delivery, with parallel developments in nanoparticle-based delivery systems and gene-editing technologies such as CRISPR/Cas9. This approach has showcased great promise in enhancing and tailoring the immune response to vaccination. Strategies to enhance the efficacy of DNA vaccines include the selection of appropriate antigens, optimizing insertion in a plasmid, and studying combinations of vaccines with conventional strategies and targeted therapies. Combination therapies have attenuated immunosuppressive activities in the tumor microenvironment and enhanced the capability of immune cells. This review provides an overview of the current framework of DNA vaccines in oncology and focuses on novel strategies, including established combination therapies and those still under development.The challenges that oncologists, scientists, and researchers need to overcome to establish DNA vaccines as an avant-garde approach to defeating cancer, are also emphasized. The clinical implications of the immunotherapeutic approaches and the need for predictive biomarkers have also been reviewed upon. We have also tried to extend the role of Neutrophil extracellular traps (NETs) to the DNA vaccines. The clinical implications of the immunotherapeutic approaches have also been reviewed upon. Ultimately, refining and optimizing DNA vaccines will enable harnessing the immune system's natural ability to recognize and eliminate cancer cells, leading the world towards a revolution in cancer cure.

show abstract

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies

Cited by 35 publications

References 132 publications

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy

Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

The future of cancer immunotherapy: DNA vaccines leading the way

Contact Info

Product

Resources

About